Medtronic Enhances AccuRhythm AI Algorithm Technology to Improve Atrial Fibrillation Detection
Medtronic, a leading medical technology company, has recently announced new enhancements to its AccuRhythm AI algorithm technology in Western Europe. These enhancements aim to improve the detection of false alerts for atrial fibrillation (AF) while preserving the accuracy of true AF alerts.
The AccuRhythm AI algorithm is an artificial intelligence system that improves the accuracy of heart rhythm event data collected from the Medtronic LINQ II insertable cardiac monitor (ICM). This technology allows physicians to better care for patients with abnormal heart rhythms.
The LINQ family of insertable cardiac monitors provides continuous, long-term monitoring for patients at an increased risk of abnormal heart rhythms. These patients may experience infrequent symptoms such as dizziness, palpitations, syncope (fainting), chest pain, or have had a cardioembolic stroke of unknown cause with suspected AF. Long-term monitoring or ongoing management is essential for these patients.
In 2022, Medtronic introduced AccuRhythm AI algorithms specifically targeting the most common false alerts in ICMs, AF, and Pause (asystole). These algorithms have already shown to reduce false alerts by up to 84%, saving clinicians in Western Europe approximately 160 hours of clinic review time annually for every 100 LINQ II patients.
AF and Pause generate approximately 90% of false alerts in the ICM space. With the recent enhancement to the AF algorithm, Medtronic anticipates a further reduction in clinic review time by an additional 40 hours, bringing the total time-saving for the clinic to 200 hours annually.
Medtronic developed the AccuRhythm AI platform and algorithms using its extensive database of more than one million electrocardiogram heart rhythm episodes. The company will continue to apply AccuRhythm AI in the cloud, automatically facilitating seamless care for patients.
Recognizing its innovative contributions, AccuRhythm AI algorithm technology was recently named the “Best New Monitoring Solution” at the 7th annual MedTech Breakthrough Awards program.
With these advancements, Medtronic is revolutionizing the detection and management of atrial fibrillation, ultimately improving patient care and outcomes.